Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Innate Pharma Regains SAR'579 Rights For AML As Sanofi Proposes €15M Strategic Equity Investment

Author: Benzinga Newsdesk | April 23, 2025 01:45am
  • Innate to regain its rights on CD123 targeting ANKET® SAR443579 (SAR'579) /IPH6101 currently in development for AML
  • Potential investment of up to €15M by Sanofi in Innate Pharma through a capital increase, subject to market conditions
  • Sanofi to continue development of BCMA targeting ANKET® program in autoimmune indications
  • Innate still eligible for more than €1 billion R&D and commercial milestones

Posted In: IPHA SNY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist